Introducing BIOiSIM®

BIOiSIM® is a first-in-class 'virtual drug development engine' that offers unprecedented value for the drug development industry by narrowing down the number of drug compounds that offer anticipated value for the treatment or cure of specific illness or disease.

“At a time when numerous smaller organizations are over-selling their AI efforts as cure-alls, I found VSL's down-to-earth but competent and insightful approach very refreshing...I would not hesitate to recommend them for organizations looking for professional and knowledgeable external ML solutions.”

- Associate Director at Genentech
BIOiSIM Offerings

How can we help you?

We provide technology enabled services to address your translational challenges guided by our unique Translational Index® capability. Engage with our professionals to quickly impact your program's journey toward more successful clinical trial outcomes.

Speak with a Sales representative >

We partner with organizations to co-develop new drugs using our platform to predict translation and reduce R&D waste. These deep collaborations significantly de-risk the selection of new candidates and shorten development time.

Contact our Corporate Development team >
Welcome To BIOiSIM
Our Proven Platform

Our models are built on data from thousands of compounds across 7 species, leading to a robustness rarely seen in the industry.

Early Insights

The BIOiSIM® platform can be used before preclinical animal trial start, allowing earlier insights and savings in expensive outsourced experimentation.

Artificial Intelligence and Mechanistic Models

VeriSIM Life has shown that the best models are developed by using a hybrid mixed-model approach to drug insights, leading to greater accuracy and scalability.

Great Translatability

With a focus on human outcomes, the platform has at its core a translability engine that transforms insights across species.

Continuous Development

The team employees a continuous improvement process to iterate on data stability, improve models, and provide an always up-to-date software service.

Fast Model Development

The flexibility of the platform and generations of customer-ready tools allows for development of custom models and validations within weeks.

BIOiSIM® enables your team with a novel platform that focuses  your development efforts on the drug compounds that are more likely to deliver on the  anticipated value for the treatment or cure  of a specific disease.

5 years graph10 years graph
With VeriSIM
~10 years
<5 years
Additional Benefits
Specific to desired output

With our framework, we can quickly develop custom, specific models.

Trained on diverse data across various animal and human species

Validated with both FDA and proprietary compounds.

Expanding feature set

We are always adding new functionality and expanding the domain of applicability.

Multiple routes of administration

We simulate various routes of administrations such as IV, oral, and transdermal and others.

Rapid result generation

Our platform is cloud-based and generates predictions in seconds.


Our model extracts conclusions from complex and convoluted data.

Give your development pipeline an edge

Speak to one of our experts today


The ‘credit score’

for drug development

Our “hybrid AI” platform, BIOiSIM®, and its groundbreaking Translational Index™ technology, are helping de-risk drug design and development – bringing more successful therapies from the scientist’s bench to the patient’s bedside.


Meaningful outcomes powered by BIOiSIM

VeriSIM Life’s first-in-class, drug decision engine, BIOiSIM, offers actionable insights of unprecedented value to the drug development industry.

Increase clinical success, boost translatability

Avoid the design and pursuit of dead end candidates. Guide decision-making with BIOiSIM’s Translational Index™, which advances only the most promising drug candidates through R&D to investigational new drug (IND) application.

Earlier insights, faster drug R&D

BIOiSIM's integrated drug design and development platform identifies new drug candidates with clinical success designed in from day one, while flexibly adapting to address a range of translation challenges – reducing the time it takes to get to IND status by an average of 2.5 years.

Reduce waste, lower costs

With greater accuracy and scalability, BIOiSIM’s robust, hybrid AI/ML engine reduces the need for unnecessary in vivo experimentation, representing a $3 million cost savings when compared to conventional testing.

The BIOiSIM advantage

Predictive insights and groundbreaking intelligence for drug R&D

Get Started
+ Trillion

Novel drug discovery search space


Real validation simulations and counting


Simulation scenario capacity

% More Accurate

Than other non-AI enhanced models


Get to IND status 2.5 years faster

BIOiSIM® 24 platform


Breakthrough AI to advance & de-risk R&D translation

The BIOiSIM platform combines a vast chemical search space, thousands of validation data sets, multi-compartmental models, machine learning, deep learning and large language models to achieve next-level chemical and biological relevance for drug design and translation agnostic to indication or modality.

AltlasGEN™ Novel Drug Designer

Synergistically marries powerful novel drug design chemistry with biological validation to discover clinically successful novel therapies.

Learn More
Translational Index

VeriSIM Life’s Translational Index informs preclinical research and development decisions, akin to the role a FICO credit score plays in evaluating consumer creditworthiness. The Translational Index score is a multi-metric synthesis of a compound’s likely therapeutic effect, including its safety and efficacy.

Hybrid mechanistic model & artificial intelligence engine

Integrates the inferential and extractive strengths of machine learning techniques with deterministic, mechanistic bio- and physiological models to yield more informed and predictive results than empirical science alone

Minimalistic generalization

Provides predictions without the need for large empirical datasets that are translatable across different species, routes of administration and therapeutic areas, greatly reducing overfit and specialization.

Continuous benchmarking  & learning

Undergoes frequent algorithm checks to reinforce learning, while tracking changes to predictiveness baselines; ongoing training and validation simulations allow for continuous learning and accuracy.

Accessible synthesis & scalability

Drives high-value decisions through the platform’s cloud-based computational system – fully scalable, optimized for high-speed processing, and supporting 800 billion total potential simulation scenarios.

Cross-disciplinary, science & data backbone

Preserves scientific context and maintains structural integrity, boasting a growing, proprietary, structure-related data lake for >3M+ compounds, >5000+ unique animal and human validation datasets, physiological parameters of 196+ different subject populations. Uniquely augmented with relevant synthetic data.

Partnerships and services

Unified technology, accessible in a range of ways

Get Started
New drug partnerships

We partner with biotech and pharma clients to identify successful novel candidates for difficult targets. Collaborate with a discovery enabler with the unique ability to merge biological relevance with target engagement chemistry, designing in clinical success from day one.

Platform-enabled services

We tailor our BIOiSIM-enabled services and Translational Index technology to address your organization’s specific translational challenges and help you achieve more successful clinical trial outcomes.

Translational Index Scorecard

With compound structure data only, BIOiSIM can predict multiple aspects of translatability across multiple animal species and for humans. See how your candidate scores!

Collaborative asset development

We partner with organizations to co-develop new drugs using the BIOiSIM platform to more accurately predict translatability and reduce R&D waste. These deep collaborations significantly de-risk the selection of new candidates and shorten development time.

Helping our customers bring better drugs to market, faster

Get Started

Our mission at Debiopharm is to develop tomorrow’s standard of care for cancer and improve patient quality of life. Accelerating the translation of our research to clinical success is a priority, and our work with VeriSIM Life is focused on this critical objective. With insights from the BIOiSIM platform, we believe our innovative therapies will rapidly move closer to addressing the unmet needs of cancer patients worldwide.

Dr. Valerie Nicolas, Deputy to the Head of Translational Medicine at Debiopharm

Ready to transform your Organization’s preclinical drug R&D?

Let’s talk